Neurocrine BiosciencesNASDAQ: NBIX is a biopharmaceutical company founded in 1992 and located in San Diego, California. The company focuses on therapies for neurological and endocrinediseases and disorders. A public company is a company owned by the public rather than by a relatively few individuals. ... NASDAQ (originally an acronym for National Association of Securities Dealers Automated Quotations ) is a U.S. electronic stock exchange. ... The current version of the article or section reads like an advertisement. ... The structure of insulin Biotechnology is a technology based on biology, especially when used in agriculture, food science, and medicine. ... Employment is a contract between two parties, one being the employer and the other being the employee. ... This page as shown in the aol 9. ... NASDAQ (originally an acronym for National Association of Securities Dealers Automated Quotations ) is a U.S. electronic stock exchange. ... San Diego County in the Southwest corner of California. ... Official language(s) English Capital Sacramento Largest city Los Angeles Area Ranked 3rd - Total 158,302 sq. ... Neurology is a branch of medicine dealing with disorders of the central and peripheral nervous systems. ... The endocrine system is a control system of ductless endocrine glands that secrete chemical messengers called hormones that circulate within the body via the bloodstream to affect distant organs. ... A disease is an abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person afflicted or those in contact with the person. ... Disorder may refer to : A disease, in medicine Randomness (lack of order), in information theory This is a disambiguation page — a list of pages that otherwise might share the same title. ...
Neurocrine Biosciences (NBIX:Nasdaq - news - research) announced a first-quarter loss that was narrower than a year ago, despite a huge drop in revenue, as the company's core product marches forward in the drug approval process.
Neurocrine had a first-quarter net loss of $12.4 million, or 35 cents a share, which is a penny better than the 36-cent loss expected by analysts and the loss of $13.4 million, or 43 cents a share, a year ago.
Neurocrine's research and development expenses plunged in the quarter, coming in at $26.4 million, down 45.3% from the $48.3 million it spent a year ago.
Feeds |
Contact